Published • loading... • Updated
Neuland Laboratories partners with LIR Life Sciences for transdermal GLP-1 peptide development
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Neuland Laboratories partners with LIR Life Sciences for transdermal GLP-1 peptide development
Neuland Laboratories, a contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences Corp, a Canada-based biotechnology company focused on obesity treatments, to advance its cell-penetrating peptide (CPP) platform. As part of the partnership, Neuland Laboratories will develop, test and manufacture CPPs to support pharmacokinetic (PK) and pharmacodynamic…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
